![ChemicalBook](https://m.chemicalbook.com/Scripts/New/img/logo.png)
![Вориностат структурированное изображение](/CAS/GIF/149647-78-9.gif)
Вориностат
- английское имяVorinostat
- CAS №149647-78-9
- CBNumberCB3506806
- ФормулаC14H20N2O3
- мольный вес264.32
- EINECS682-505-1
- номер MDLMFCD00945317
- файл Mol149647-78-9.mol
химическое свойство
Температура плавления | 161-162°C |
плотность | 1.2 |
RTECS | RG8835000 |
температура хранения | -20°C |
растворимость | DMSO: ≥15mg/mL |
форма | powder |
пка | 9.48±0.20(Predicted) |
цвет | white to tan |
Мерк | 14,10034 |
Стабильность | Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 6 months. |
ИнЧИКей | WAEXFXRVDQXREF-UHFFFAOYSA-N |
Справочник по базе данных CAS | 149647-78-9(CAS DataBase Reference) |
Словарь онкологических терминов NCI | suberoylanilide hydroxamic acid; vorinostat |
FDA UNII | 58IFB293JI |
Словарь наркотиков NCI | vorinostat |
Код УВД | L01XH01 |
Коды опасности | T | |||||||||
Заявления о рисках | 61-68 | |||||||||
Заявления о безопасности | 53-36/37-45 | |||||||||
WGK Германия | 3 | |||||||||
кода HS | 29280000 | |||||||||
Банк данных об опасных веществах | 149647-78-9(Hazardous Substances Data) | |||||||||
NFPA 704: |
|
рисовальное письмо(GHS)
-
рисовальное письмо(GHS)
-
сигнальный язык
опасность
-
вредная бумага
H341:Предполагается, что данное вещество вызывает генетические дефекты.
H360:Может отрицательно повлиять на способность к деторождению или на неродившегося ребенка.
-
оператор предупредительных мер
P201:Беречь от тепла, горячих поверхностей, искр, открытого огня и других источников воспламенения. Не курить.
P308+P313:ПРИ подозрении на возможность воздействия обратиться за медицинской помощью.
Вориностат химические свойства, назначение, производство
Описание
Vorinostat is the first drug in a new class of anti-cancer agents that inhibit histone deacetylases (HDAC). It was launched as an oral treatment for cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent, or recurrent disease on or following two systemic therapies. HDACs are enzymes that catalyze the removal of the acetyl modification on lysine residues of proteins, including the core nucleosomal histones. Together with their counterpart histone acetyltransferases (HATs), HDACs regulate the acetylation level of the histones, which plays an important role in the regulation of chromatin plasticity and gene transcription. Hypoacetylation of histones is associated with a condensed chromatin structure resulting in the repression of gene transcription, whereas acetylated histones are associated with a more open chromatin structure and activation of transcription. In some cancer cells, there is an overexpression of HDACs, resulting in hypoacetylation of histones. Inhibitors of HDAC are thought to transcriptionally reactivate dormant tumor-suppressor genes by allowing for the accumulation of acetyl groups on histones and an open chromatin structure. Vorinostat inhibits the enzymatic activity of HDAC1, HDAC2, HDAC3, and HDAC6 at nanomolar concentrations (IC50 <86 nM). In vitro, it induces growth arrest, differentiation or apoptosis in a variety of tumor cells. In addition, vorinostat inhibits tumor growth in animal models bearing solid tumors, including breast, prostate, lung and gastric cancers, as well as hematologic malignancies such as multiple myeloma and leukemias.Химические свойства
White Crystalline SolidИспользование
Vorinostat, a histone deacetylase (HDAC) inhibitor from Merck, was approved for the treatment of cutaneous T-cell lymphoma (CTCL), a type of non-Hodgkin’s lymphoma. Vorinostat was shown to inhibit HDAC1, HDAC2, HDAC3 and HDAC6 at nanomolar concentrations. HDAC inhibitors are potent differentiating agents toward a variety of neoplasms, including leukemia and breast and prostate cancers.Определение
ChEBI: A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).Общее описание
Histones are proteins around which DNA is wound in the process of packing DNA into the nucleus. They also havea role in regulating the transcription of genes, and this iscontrolled by the covalent modifications acetylation, phosphorylation,and methylation to which they are subject.Vorinostat fits the basic pharmacophore for the HDACis, which consists of a hydrophobic cap regionconnected to a zinc coordinating functionality by a hydrophobiclinker.The hydroxamic acid functionality iscapable of bidendate binding to zinc present in the enzymeand is a major factor in the overall binding of the compound.The compound inhibits HDAC1, 2, 3, and 6 classes of thisenzyme with nanomolar (<86 nM) IC50 values.
The agent is given orally and is available in 100-mg capsulesfor the treatment of cutaneous T-cell lymphoma. Thebioavailability is 43%, and the agent is 71% bound toplasma proteins. Extensive metabolism of the agent occursto give the O-glucuronide of the hydroxamic acid functionand 4-anilino-4-oxobutanoic acid with minimal involvementof isozymes of CYP. The metabolites, both of whichare inactive, are eliminated in the urine and the drug has aterminal elimination half-life of 2 hours. The most commonlyreported adverse effects are fatigue, diarrhea, andnausea.
Вориностат поставщик
поставщик | телефон | страна | номенклатура продукции | благоприятные условия |
---|---|---|---|---|
+86 13288715578 +8613288715578 |
China | 12459 | 58 | |
+86-19930503253; +8619930503252 |
China | 5838 | 58 | |
+86-17331933971 +86-17331933971 |
China | 2503 | 58 | |
+86-15532196582 +86-15373005021 |
China | 2989 | 58 | |
+undefined18602966907 | China | 1000 | 58 | |
+undefined86-15315557071 | China | 983 | 58 | |
+86-0086-57187702781 +8613675893055 |
China | 219 | 58 | |
+86-0371-55170693 +86-19937530512 |
China | 21670 | 55 | |
025-83697070 | CHINA | 3012 | 60 | |
025-85710122 17714198479 | CHINA | 885 | 55 |